CD30 is already the target of brentuximab vedotin (BV), an antibody-drug conjugate that has been approved for relapsed/refractory Hodgkin’s Lymphoma and anaplastic large T-cell lymphomas, cutaneous T-cell lymphoma andCD30+ peripheral T-cell lymphomas. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.